about
Role of Peroxisome Proliferator-Activated Receptors in Inflammation ControlA retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor liContrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prDownregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposisIdentification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control regionInhibitory effect of peroxisome proliferator-activated receptor gamma agonist on ochratoxin A-induced cytotoxicity and activation of transcription factors in cultured rat embryonic midbrain cellsSAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis.Lipoprotein lipase, a key role in atherosclerosis?Peroxisome proliferator-activated receptor gamma1 (PPAR-gamma1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation.Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection.Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.Effect of plant extracts on H2O2-induced inflammatory gene expression in macrophages.Control of macrophage activation and function by PPARs.Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis.Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancerPredictive computational modeling of the mucosal immune responses during Helicobacter pylori infectionPPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effectPeroxisome proliferator-activated receptors and cancer: challenges and opportunitiesDeletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane diseasePPARgamma as a new therapeutic target in inflammatory bowel diseasesEmerging drugs for the treatment of ulcerative colitisStimulatory Effects of Peroxisome Proliferator-Activated Receptor-gamma on Fcgamma Receptor-Mediated Phagocytosis by Alveolar Macrophages.Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells.Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages.Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects.Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.Peroxisome proliferator-activated receptor gamma and chicken ovalbumin upstream promoter transcription factor II negatively regulate the phosphoenolpyruvate carboxykinase promoter via a common element.Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists.Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease.PPARγ in Inflammatory Bowel Disease.A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation.Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARα in mice.Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis.Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands.Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility.Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation.Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity.
P2860
Q24796541-EF06C071-BE34-4F60-8F0F-E2F22912ACD6Q24806395-F6FAD40D-5623-478D-AC9E-A6A6F0E0F452Q24812924-B2155C09-921B-4724-B112-8574FA5ABDCBQ24814458-126046AB-A860-4547-8D8D-E0EF0EBD5DE8Q28343603-89112E69-D65F-41B5-8EFF-83D57F5E45B4Q28566307-1B6BE30C-51B4-4E17-ACBC-4AA3B31E9FFBQ30423660-E12357BD-F3EA-425E-9C2E-6F8BE5C653F7Q30820478-64FC0A49-CFF9-45F5-BDB2-685D5025A6A6Q32019780-3EA504A4-144B-4895-A5C4-BC2FA757DE4EQ33524893-3FED9007-6DBA-43F1-9557-5EA0116811E5Q33780711-BA617F05-D160-48AF-B998-99E34409F3BAQ33930022-D1B31F55-0DE2-44BF-93A4-4D06E094F54AQ33962601-5DE42EBA-1F32-4AC9-9234-7A0AC23B1E80Q34466845-6F8804A7-608D-47D4-A1CE-0A09FE5BF0ABQ34764285-C4D7CD8D-CD53-4E68-80DE-4E9C2FC56C49Q34878637-2F7B45C1-FEDE-4B25-9321-0172174F9AC6Q34988965-123D40A5-BB7D-492A-B07E-E8714ADFB096Q35045267-7670E071-2663-4367-B960-B45BD69171CCQ35210023-BBFEEE72-F122-4EC6-9836-EA361C6D0BC9Q35557407-5F0E7D62-41E0-4EAB-A389-231D97A95900Q35768913-6DA68E2C-5D60-4DBF-B202-82305B0FE4E9Q36039436-D1B66C33-B392-46CA-AD38-61BD6C19D15EQ36417564-D29ACBBB-1232-48AC-920C-1451A00CA832Q36836697-0C173468-D096-4A89-9916-2D3D45F77959Q37417623-8A3A28E7-59D7-4EC7-B893-08D1C77CF798Q37427307-00596034-159C-47CA-95F8-0DFBD23A7B7BQ38246264-4DC67BD5-2A9F-40D8-B76E-69121AC7F50FQ40242074-5F929923-21D7-4E25-9AD4-C523FA0DF2C8Q40286857-0D53A560-24FD-4F45-95B3-64643326E3A4Q40799456-FBA9CC08-C3A9-4DFA-9160-2B1E6567D9B1Q40816289-FCA66EFC-C59F-4E58-8CE9-22100030D596Q40820351-CB2D5416-53AA-4192-B8A9-BEDAAE90F3ECQ42038488-19459180-205B-4172-8511-04C19E34600DQ42653520-5B5AA4AC-2EBC-464A-B73C-DEE71643E82FQ42742598-8F4490C6-5670-4DAC-B69B-37A871964669Q42808012-6AE8239F-7105-407D-8483-976E056B0B6DQ43811215-7E6303E2-7C64-46EE-A7CB-2016F0CA61DBQ43909419-2C3BC41A-4BBC-490D-BD0D-3682047914B4Q43963761-ED3A5C9D-5DD3-4124-9356-1BCC91B5CC66Q43970140-CB554972-2861-4028-83DC-CC4BC7B5A90E
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
PPARgamma in monocytes: less pain, any gain?
@en
type
label
PPARgamma in monocytes: less pain, any gain?
@en
prefLabel
PPARgamma in monocytes: less pain, any gain?
@en
P1433
P1476
PPARgamma in monocytes: less pain, any gain?
@en
P2093
Spiegelman BM
P304
P356
10.1016/S0092-8674(00)81567-6
P407
P577
1998-04-01T00:00:00Z